Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | PHASE1 | RECRUITING | 24 | — | — | Nov 15, 2020 | Dec 31, 2027 | Feb 14, 2025 | 1 | Taiwan |
assessment of adverse events
| Arm | Type | Description |
|---|---|---|
| PB103 (donor-derived NK cells) infusion | EXPERIMENTAL | Cohort 1: 0.5×10\^9，Cohort 2:1×10\^9 or Cohort 3: 1.5×10\^9 cells |
| Name | Type | Description |
|---|---|---|
| donor-derived NK cell infusion | BIOLOGICAL | PB103 administrations will be separated by 4-week interval |
Inclusion Criteria: Recipient: 1. Recipients (Subjects) are between 20-70 years of age. 2. Related donor: 6/6 matched at HLA-A, -B and -DRb1 or haploidentical donor ≥ 4/8 match at HLA-A, -B, -C and -DRb1 3. Signed informed consent. 4. Subjects with histologically or cytologically confirmed non -sm...